There seems to be widespread confusion in biotechs about off-label communication—despite the rules being clear. Sales representatives may only discuss information that appears on the FDA-approved label. Off-label promotion by sales is prohibited, regardless of intent or context. Medical Science Liaisons may discuss off-label information only when a physician initiates an unsolicited scientific inquiry. When marketing strategies blur the line between sales and medicine, companies expose themselves to regulatory risk. For pharma marketers and physicians alike, compliance isn’t complicated—it just requires respecting well-established boundaries.
If you have been in pharma marketing for a while, you’re aware of what sales reps and MSLs can say and not say. Most big pharma companies have clear boundaries and checks and balances. However, smaller, typically start-up, biotech companies are pushing the regulatory envelope because they face intense performance pressures and believe the FDA is too understaffed to catch them. That would be a huge mistake.
If it’s not on the FDA-approved label, sales reps cannot talk about it. Period.
Not “hint at it.”
Not “frame it creatively.”
Not “answer the question if it comes up.”
Not “leave behind a study and let the doctor connect the dots.”
They. Cannot. Talk. About. It.
And no amount of internal rationalization, competitive pressure, or “but everyone else is doing it” changes that.
Sales ≠ Science (And That’s the Point)
Sales representatives are responsible for promoting approved indications using approved claims supported by the label. That’s the deal. That’s the boundary. That’s why the FDA keeps sending warning letters that all sound eerily familiar.
When reps cross into off-label territory—even with good intentions—they’re not being “helpful.” They’re exposing the company to regulatory risk and themselves to personal consequences.
And let’s be honest: most of these violations don’t happen because the rules are unclear. They happen because the pressure to sell is louder than compliance training.
Where Marketers Keep Screwing This Up
Here’s where pharma marketers often make things worse:
- Creating materials that imply off-label benefits without explicitly stating them
- Over-indexing on disease education that suspiciously mirrors off-label use
- Encouraging reps to “drive scientific conversations,” they are not allowed to have
If a rep needs a flow chart to explain why a claim is “technically compliant,” it probably isn’t.
Now, the Part Everyone Gets Wrong: MSLs
This is where nuance matters—and where confusion reigns.
Medical Science Liaisons (MSLs) can discuss off-label information—but only under very specific conditions.
Here’s the rule people keep glossing over:
The conversation must be unsolicited and initiated by the physician.
That’s it. That’s the gate.
- The physician asks a question
- The question is clearly scientific or clinical
- The MSL responds with balanced, non-promotional, data-driven information
No proactive pitching.
No “planting the seed.”
No tag-teaming with sales to magically create a “spontaneous” question.
If the MSL steers the conversation there, it’s not unsolicited.
If sales sets it up, it’s not unsolicited.
If marketing designs a strategy around it, congratulations—you just turned medical into promotion.
Physicians: This Isn’t a Game of Wink-Wink, Nod-Nod
Physicians aren’t passive players here either.
You already know reps can’t talk off-label. Trying to coax them into it—or pretending not to know the rules—puts everyone in a bad position.
If you want off-label data:
- Ask an MSL directly
- Ask in a scientific context
- Expect a balanced answer, not a sales pitch
That separation exists for a reason.
This isn’t complicated. It’s just inconvenient.
- Sales talk label. Full stop.
- MSLs talk science—but only when asked.
- Marketing should stop pretending there’s a clever workaround.
The FDA doesn’t care how competitive your market is.
They don’t care that physicians “already know.”
And they definitely don’t care that “this is how it’s always been done.”
The rules haven’t changed.
The enforcement hasn’t softened.
And the warning letters aren’t accidents.
If pharma wants credibility—with regulators, physicians, and patients—it starts by respecting a line that’s been clearly drawn for decades.
And staying on the right side of it.

